Loading clinical trials...
Loading clinical trials...
Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide
It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Medizinische Hochschule Hannover
Hanover, Germany
Start Date
February 1, 2007
Primary Completion Date
December 1, 2008
Completion Date
December 1, 2008
Last Updated
February 4, 2009
12
ESTIMATED participants
Cyclophosphamide
DRUG
Lead Sponsor
Hannover Medical School
NCT05906524
NCT04601610
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions